April 22, 2011 – The U.S. Food and Drug Administration (FDA) has cleared the Trifecta valve, by St. Jude Medical. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart. The valve was designed for excellent hemodynamic performance (the optimization of blood flow through the valve) and long-term durability. To ensure the structural integrity of the valve, it is constructed using a polyester and tissue-covered titanium stent, or base. The valve features leaflets manufactured from pericardial tissue attached to the exterior of the valve stent. This design allows the leaflets to open more fully and efficiently, mimicking the performance of a healthy aortic heart valve and limiting tissue abrasion through tissue-to-tissue (stent-to-leaflet) contact. Also contributing to the valve’s durability, it offers the Linx AC Technology, an anticalcification treatment designed to reduce tissue mineralization (hardening), one of the primary causes of valve deterioration. It also offers several features that improve the ease of implantation, including the valve’s unique holder, designed to improve visibility and cuff access for suturing, and customized sizes. “Physicians around the world have already voiced tremendous excitement and satisfaction with the Trifecta valve,” said Frank J. Callaghan, president of the St. Jude Medical cardiovascular division. “Trifecta has demonstrated outstanding hemodynamic performance and has improved the lives of patients with aortic valve disease.” The valve was approved by regulatory authorities in Europe and Canada in 2010. For more information: www.sjm.com
Technology | April 22, 2011
FDA Clears Trifecta Stented Tissue Aortic Valve
News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
Feature | Cardiovascular Surgery| November 16, 2015 | Saurabh D. Ashier, PA-C, Keck Medical Center USC
We are approaching 20 years since the introduction of endoscopic vein-graft harvesting (EVH) as a method of vessel ha
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
Feature | Heart Valve Repair| November 12, 2015 | Dave Fornell
The advent of transcatheter valve repair and replacement technologies is one of those rare instances where there is a
News | Cardiovascular Surgery| November 10, 2015
MC3 Cardiopulmonary announced it has completed the acquisition and transfer of all assets associated with Terumo...
News | Heart Valve Repair| November 10, 2015
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a randomized trial studying a new...
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
News | Left Atrial Appendage (LAA) Occluders| October 28, 2015
SentreHeart Inc. announced that it has received CE Mark approval for the Lariat Surgical Left Atrial Appendage (LAA)...
News | Ventricular Assist Devices (VAD)| October 28, 2015
St. Jude Medical Inc. announced the company has received CE Mark approval for the HeartMate 3 Left Ventricular Assist...
News | Heart Valve Repair| October 27, 2015
A large observational registry found that initial aortic valve replacement (AVR) in asymptomatic patients with severe...